


Measles elimination status

2016 eliminated
2017 eliminated



Source: European Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report: www.euro.who.int/7thrv

Rubella elimination status


2016 eliminated
2017 eliminated



Source: European Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report: www.euro.who.int/7thrv

Measles and rubella surveillance

National case-based surveillance for measles, rubella and CRS
Lab confirmation for diagnosis of measles, rubella and CRS



Source: WHO/UNICEF Joint Reporting Form on Immunization, 2017

Demographic information, 2017

| | |
|------------------|-----------|
| Total population | 2 079 976 |
| < 1 year old | 20 233 |
| < 5 years old | 106 349 |

Source: World Population Prospects: The 2017 Revision, New York, United Nations


Measles and rubella immunization schedule, 2017

| | Vaccine | Schedule | Year of introduction | |
|-------------------------------|---------|-----------|----------------------|------|
| MCV1 | MMR | 12 months | MCV2 | 1974 |
| MCV2 | MMR | 5 years | RCV | 1972 |
| Measles vaccination in school | | | | No |

Source: Immunization schedule, WHO, Data and Statistics, Immunization Monitoring and Surveillance (http://www.who.int/immunization/monitoring_surveillance/data/en/)

MMR = measles-mumps-rubella vaccine; MCV1 = first dose measles-containing vaccine; MCV2 = second dose measles-containing vaccine; RCV = rubella-containing vaccine

Measles and rubella cases and immunization coverage, 2008–2017




Source: Disease incidence and immunization coverage (WUENIC), WHO, Data and Statistics, Immunization Monitoring and Surveillance

(http://www.who.int/immunization/monitoring_surveillance/data/en/)

MCV1 = first dose of measles-containing vaccine
MCV2 = second dose of measles-containing vaccine


Definition used for an outbreak

Two or more epidemiologically linked confirmed cases



Source: Measles and rubella elimination Annual Status Update report, 2017

Confirmed measles cases by month of onset, 2013-2017




Source: CISD 2017



Measles and rubella elimination country profile


Slovenia

Measles cases by first subnational level, 2017



Source: Measles and rubella elimination Annual Status Update report, 2017


Measles genotypes by first subnational level, 2017



Source: MeaNS 2017

Note: The dots in the maps are placed randomly within the administrative regions.
Map disclaimer: The boundaries and names shown and the designations used on the maps do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Measles cases by age group and vaccination status, 2017



Source: Measles and rubella elimination Annual Status Update report, 2017
Note: Excludes imported cases

Sources of infection, 2017

| | Measles | Rubella |
|-----------------------|---------|---------|
| Imported | 2 | 0 |
| Import-related | 6 | 0 |
| Unknown/ Not reported | 0 | 0 |
| Endemic | 0 | 0 |

Source: Measles and rubella elimination Annual Status Update report, 2017

Information on CRS, 2017



Source: Measles and rubella elimination Annual Status Update report, 2017
CRS = congenital rubella syndrome

Measles and rubella elimination country profile Slovenia

Measles incidence, epidemiologic and virologic characteristics, 2013-2017

| | Suspected measles cases | Confirmed measles cases | | | | Discarded as non-measles | Measles incidence | Genotypes detected |
|------|-------------------------|-------------------------|------------|------------|-------|--------------------------|-------------------|--------------------|
| | | Laboratory | Epi-linked | Clinically | Total | | | |
| 2013 | 13 | 1 | 0 | 0 | 1 | 12 | 0 | D8 |
| 2014 | 113 | 51 | 1 | 0 | 52 | 61 | 21.8 | D8 |
| 2015 | 86 | 17 | 1 | 0 | 18 | 68 | 4.4 | D8 |
| 2016 | 15 | 1 | 0 | 0 | 1 | 14 | 0 | B3 |
| 2017 | 37 | 8 | 0 | 0 | 8 | 29 | 2.9 | B3 |

Source: Measles and rubella elimination Annual Status Update report, 2013-2017
Incidence calculated per 1 million population
ND = Data not available; NA= Not applicable

Measles surveillance and laboratory performance indicators, 2013-2017

| | Discarded non-measles rate | % 1st sub-national unit with ≥ 2 discarded cases | % cases with adequate laboratory investigation | % origin of infection known | # specimen tested for measles | % positive for measles | Rate of viral detection | % WHO and proficient labs |
|------|----------------------------|--|--|-----------------------------|-------------------------------|------------------------|-------------------------|---------------------------|
| 2013 | 0.6 | ND | 100% | 100% | 13 | 7.7% | 100% | 100% |
| 2014 | 3 | 55% | 98% | 100% | 112 | 45.5% | 100% | 100% |
| 2015 | 3.6 | 55% | 94% | 66% | 85 | 20% | 100% | 100% |
| 2016 | 0.7 | 66.7% | 100% | 100% | 15 | 6.7% | 100% | 100% |
| 2017 | 1.4 | 44.4% | 100% | 100% | 37 | 21.6% | 100% | 100% |

Source: ASU 2013-2017 and communication with the country
ND = Data not available; NA= Not applicable
A proficient laboratory is WHO accredited and/or has an established quality assurance programme with oversight by a WHO accredited laboratory

Rubella incidence, epidemiologic and virologic characteristics, 2013-2017

| | Suspected rubella cases | Confirmed rubella cases | | | | Discarded as non-rubella | Rubella incidence | Genotypes detected |
|------|-------------------------|-------------------------|------------|------------|-------|--------------------------|-------------------|--------------------|
| | | Laboratory | Epi-linked | Clinically | Total | | | |
| 2013 | 11 | 0 | 0 | 0 | 0 | 11 | 0 | NA |
| 2014 | 12 | 0 | 0 | 0 | 0 | 12 | 0 | NA |
| 2015 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | NA |
| 2016 | 6 | 0 | 0 | 0 | 0 | 6 | 0 | NA |
| 2017 | 7 | 0 | 0 | 0 | 0 | 7 | 0 | NA |

Source: Measles and rubella elimination Annual Status Update report, 2013-2017
Incidence calculated per 1 million population
ND = Data not available; NA= Not applicable

Rubella surveillance and laboratory performance indicators, 2013-2017

| | Discarded non-rubella rate | % 1st sub-national unit with ≥ 2 discarded cases | % cases with adequate laboratory investigation | % origin of infection known | # specimen tested for rubella | % positive for rubella | Rate of viral detection | % WHO and proficient labs |
|------|----------------------------|--|--|-----------------------------|-------------------------------|------------------------|-------------------------|---------------------------|
| 2013 | 0.6 | ND | 100% | NA | ND | 0% | NA | 100% |
| 2014 | 0.6 | 0% | 100% | NA | 12 | 0% | NA | 100% |
| 2015 | 0.1 | 0% | 100% | NA | 86 | 0% | NA | 100% |
| 2016 | 0.3 | 11.1% | 100% | NA | 6 | 0% | NA | 100% |
| 2017 | 0.3 | 33.3% | 100% | NA | 7 | 0% | NA | 100% |

Source: ASU 2013-2017
ND = Data not available; NA= Not applicable
A proficient laboratory is WHO accredited and/or has an established quality assurance programme with oversight by a WHO accredited laboratory

RVC comments, based on 2017 reporting

The Regional Verification Commission for Measles and Rubella Elimination (RVC) concluded that endemic transmission of both measles and rubella remained interrupted in Slovenia in 2017 and confirmed that measles and rubella elimination has been sustained. Surveillance performance and sensitivity need to be strengthened and better documented.

Source: European Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report: www.euro.who.int/7thrv

Surveillance performance indicators and targets

- Rate of discarded cases: at least 2 discarded measles or rubella cases per 100 000 population
- % cases with adequate laboratory investigation: ≥ 80%
- % origin of infection known: ≥ 80%
- Rate of viral detection: ≥ 80%